Lorlatinib Patent Expiration
Lorlatinib is Used for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. It was first introduced by Pfizer Inc
Lorlatinib Patents
Given below is the list of patents protecting Lorlatinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lorbrena | US10420749 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US11020376 | Crystalline form of lorlatinib free base | Jul 27, 2036 | Pfizer |
| Lorbrena | US11299500 | Crystalline form of lorlatinib free base hydrate | Oct 04, 2038 | Pfizer |
| Lorbrena | US8680111 | Macrocyclic derivatives for the treatment of diseases | Mar 05, 2033 | Pfizer |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳